Call: +7 771 977 66 65, +7 705 421 2277
Sign in or Register
My basket

Astana Biomed Group, an authorized Abcam distributor in Central Asia

Abiomed homepage

  • Categories
    Signal Transduction
    Cancer
    Epigenetics and Nuclear Signaling
    Immunology
    Cell Biology
    Cardiovascular
    Neuroscience
    Tags & Cell Markers
    Kits/ Lysates/ Other
    Developmental Biology
    Microbiology
    Biochemicals
    Secondary antibodies
    Isotype/Loading Controls
    Antibody Arrays
  • About us
  • Partners
  • Contact
    Address

    Saryarka 32, 18, 010000, Astana city, Kazakhstan

    Telephone +7 771 977 66 65, +7 705 421 2277

    Email

    laboratory@ctlab.kz, orders@abiomed.kz

Back to category
Epigenetics and Nuclear Signaling DNA methylation DNMTs

Bisdemethoxycurcumin, Apoptotic curcuminoid (ab120976)

Price and availability

167 520 ₸

Availability

Order now and get it on Thursday February 25, 2021

Bisdemethoxycurcumin, Apoptotic curcuminoid (ab120976)
  • ChIP - Anti-Histone H3 antibody - Nuclear Loading Control and ChIP Grade (ab1791)

Key features and details

  • Apoptotic anticancer, anti-inflammatory and antioxidant curcuminoid
  • CAS Number: 33171-05-0
  • Purity: > 98%
  • Soluble in DMSO to 100 mM
  • Form / State: Solid
  • Source: Synthetic

You may also be interested in

Product image
Recombinant Human Dnmt3L protein (BSA and azide free) (ab180335)
Product image
Anti-HEMK2/N6AMT1 antibody (ab238897)
Product image
Human DNMT1 Antibody Pair - BSA and Azide free (ab253568)
Product image
Recombinant human Dnmt1 protein (ab198109)

Overview

  • Product name

    Bisdemethoxycurcumin, Apoptotic curcuminoid
  • Description

    Apoptotic anticancer, anti-inflammatory and antioxidant curcuminoid
  • Alternative names

    • BDMC
    • Bisdesmethoxycurcumin
    • Curcumin III
    • Didemethoxycurcumin
  • Biological description

    Apoptotic anticancer, anti-inflammatory and antioxidant curcuminoid. Inhibits wnt activity through activation of WIF-1. Induces demethylation through DNA methyltransferase 1 inhibition. Potent and competitive aldo-keto reductase inhibitor (Ki = 22 nM).

  • Purity

    > 98%
  • CAS Number

    33171-05-0
  • Chemical structure

    Chemical Structure

Images

  • Functional Studies - Bisdemethoxycurcumin, Apoptotic curcuminoid (ab120976)
    Functional Studies - Bisdemethoxycurcumin, Apoptotic curcuminoid (ab120976)
    ab18210 staining Bcl2 in HeLa cells treated with bisdemethoxycurcumin (ab120976), by ICC/IF. Decrease of Bcl2 expression correlates with increased concentration of bisdemethoxycurcumin, as described in literature.
    The cells were incubated at 37°C for 6 hours in media containing different concentrations of ab120976 (bisdemethoxycurcumin) in DMSO, fixed with 100% methanol for 5 minutes at -20°C and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab18209 (5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Clear all

Recently viewed products

  •  
  • Product image

    Anti-Histone H2A.X (acetyl K5) + Histone H2A (acetyl K5) antibody [EPR17589] - ChIP Grade (ab177863)

  •  
  • Product image

    Alexa Fluor® 647 Anti-MHC Class II beta antibody [EPR11227] (ab203323)

  •  
  • Product image

    Recombinant human ROS1 (mutated G2032R) protein (ab206012)

  •  
  • Product image

    Recombinant Human ENPP3/B10 protein (ab159085)

  •  
  • Product image

    Recombinant human Flt3 / CD135 (R595_E596insEY) protein (Active) (ab268584)

  •  
  • Product image

    Cholinesterase Activity Assay Kit (Colorimetric) (ab235937)

Get resources and offers direct to your inbox Sign up
© 2021 Astana Biomed Group LLP. All rights reserved.